| |
Median OS, months
|
HR (95% CI)
|
P-value
|
Median PFS, months
|
HR (95% CI)
|
P-value
|
|---|
|
Age
| | | | | | |
|
< 60 years
|
69.4
|
1.54 (0.92-2.58)
|
0.100
|
11.9
|
1.00 (0.62-1.62)
|
0.976
|
|
≥ 60 years
|
18.9
| | |
13.8
| | |
|
Gender
| | | | | | |
|
Male
|
30.0
|
1.24 (0.73-2.11)
|
0.422
|
12.1.
|
0.91 (0.55-1.51)
|
0.732
|
|
Female
|
27.5
| | |
15.2
| | |
|
Performance status
| | | | | | |
|
0-1
|
57.4
|
4.09 (2.10-8.00)
|
< 0.001
|
14.5
|
2.28 (1.16-4.46)
|
0.016
|
|
2-4
|
6.3
| | |
3.6
| | |
|
B symptom
| | | | | | |
|
Absent
|
38.5
|
1.45 (0.84-2.50)
|
0.178
|
14.7
|
1.31 (0.79-2.16)
|
0.282
|
|
Present
|
15.6
| | |
7.1
| | |
|
Stage
| | | | | | |
|
1-2
|
69.4
|
1.63 (0.93-2.87)
|
0.086
|
19.1
|
1.68 (1.02-2.77)
|
0.041
|
|
3-4
|
16.6
| | |
9.5
| | |
|
Extranodal involvement
| | | | | | |
|
0-1
|
69.4
|
2.10 (1.24-3.54)
|
0.005
|
18.1
|
2.08 (1.29-3.35)
|
0.003
|
|
≥ 2
|
11.5
| | |
8.1
| | |
|
Bone marrow involvement
| | | | | | |
|
Negative
|
57.4
|
1.62 (0.93-2.79)
|
0.084
|
14.5
|
1.68 (1.02-2.76)
|
0.039
|
|
Positive
|
10.2
| | |
7.3
| | |
|
LDH
| | | | | | |
|
Normal
|
NR
|
2.89 (1.67-5.00)
|
< 0.001
|
16.0
|
1.69 (1.06-2.68)
|
0.025
|
|
Elevated
|
11.5
| | |
8.8
| | |
|
IPI
| | | | | | |
|
L, LI
|
NR
|
3.96 (2.36-6.66)
|
< 0.001
|
18.1
|
2.34 (1.47-3.74)
|
< 0.001
|
|
HI, H
|
8.1
| | |
8.1
| | |
|
PIT
| | | | | | |
|
Group 1-2
|
76.1
|
2.78 (1.67-4.62)
|
< 0.001
|
15.2
|
1.69 (1.06-2.69)
|
0.026
|
|
Group 3-4
|
10.1
| | |
9.4
| | |
|
ALC
| | | | | | |
|
≥ 1.0 × 109/l
|
69.4
|
2.19 (1.30-3.67)
|
0.003
|
18.1
|
3.01 (1.14-3.02)
|
0.012
|
|
< 1.0 × 109/l
|
15.5
| | |
7.0
| | |
- LDH, lactate dehydrogenase; IPI, International Prognostic Index; L, low; LI, low-intermediate; HI, high-intermediate; H, high; PIT, Prognostic Index for peripheral T-cell lymphoma; ALC, absolute lymphocyte count; NR, not reached; OS, overall survival; PFS, progression free survival.
